Continuous-infusion doxorubicin in the treatment of primary hepatic malignancies of childhood.
Five children with primary hepatic malignancies were treated with continuous infusions of doxorubicin administered as a single agent every 3-4 weeks. Four of five children showed positive response to therapy, manifested by decreasing tumor size and/or tumor markers; the fifth child had stable disease for 4 months. Side effects included mild nausea and vomiting and myelosuppression. No evidence of cardiotoxicity was seen with cumulative doses up to 720 mg/m2.
Neglia
J P
JP
Woods
W G
WG
D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D002408:Catheters, Indwelling; D002648:Child; D002675:Child, Preschool; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D007263:Infusions, Parenteral; D008113:Liver Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D012086:Reoperation; D000509:alpha-Fetoproteins / Q000097:blood
D000509:alpha-Fetoproteins; D004317:Doxorubicin